- Home
- CBRE vs KVUE Comparison
CBRE vs KVUE Comparison
Compare CBRE & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBRE | KVUE |
|---|---|---|
| Founded | 1906 | 2022 |
| Country | United States | United States |
| Employees | 44000 | N/A |
| Industry | Real Estate | Specialty Chemicals |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.7B | 34.9B |
| IPO Year | 2001 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CBRE | KVUE |
|---|---|---|
| Price | $136.08 | $17.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $177.86 | $19.73 |
| AVG Volume (30 Days) | 1.8M | ★ 18.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.80% |
| EPS Growth | 22.61 | ★ 40.74 |
| EPS | ★ 3.85 | 0.76 |
| Revenue | ★ $40,550,000,000.00 | $15,124,000,000.00 |
| Revenue This Year | $14.24 | $4.86 |
| Revenue Next Year | $9.06 | $2.63 |
| P/E Ratio | $35.35 | ★ $22.75 |
| Revenue Growth | ★ 13.37 | N/A |
| 52 Week Low | $108.45 | $14.02 |
| 52 Week High | $174.27 | $25.17 |
Technical Indicators
Market Signals| Indicator | CBRE | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 41.04 |
| Support Level | $135.44 | $17.20 |
| Resistance Level | $138.73 | $17.72 |
| Average True Range (ATR) | 3.46 | 0.30 |
| MACD | 1.17 | -0.03 |
| Stochastic Oscillator | 71.74 | 37.02 |
Price Performance
Historical ComparisonAbout CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About KVUE Kenvue Inc.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.